Acomplia
Acomplia (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1). Acomplia is used in the treatment of obesity and related conditions.
Consumer Information (Drugs.com) · More like this · Add to my drug list

Zimulti Information from Drugs.com
...Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation February 17, 2006 Acomplia (rimonabant) receives marketing authorisation in the European Union (PDF) sanofi-aventis Press Release June 21, 2006 FDA Advisory Committee Did...
Consumer Information (Drugs.com) · More like this · Add to my drug list

Acomplia (rimonabant) study: smoking, obesity -- one pill to treat them both?
NEW ORLEANS, LA., March 9, 2004 -- Early results of two Phase III studies with Sanofi-Synthelabo's Acomplia (rimonabant), the first in a new class of therapeutics called Selective CB1 Blockers, indicate that overweight/obese patients with untreated dyslipidemia...
News & Articles (Drugs.com) · More like this

Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Acomplia/Zimulti
...for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal products Acomplia/Zimulti. The Marketing Authorisation Holder for these medicinal products is sanofi-aventis. The CHMP adopted a new contraindication as follows:...
New Drug Applications (FDA) · More like this

Acomplia (rimonabant) Significantly Improved Glucose Control in Type 2 Diabetes Patients Treated with Insulin
PARIS, June 10, 2008 - Sanofi-aventis announced today the results of ARPEGGIO, the first trial of rimonabant in patients with type 2 Diabetes, not adequately...
Clinical Trial Results (FDA) · More like this